Atara closes expanded tab-cel partnership with Pierre Fabre; receives ~$27M upfront, up to $640M total

Atara Biotherapeutics, Inc.

Pierre Fabre gets development, manufacturing, commercialization rights for tab-cel in US and all remaining markets.
Atara receives ~$27M cash upfront and initial inventory purchase; potential milestones up to $640M total.
Potential $100M in regulatory milestones through BLA approval; significant double-digit tiered royalties on net sales.
Pierre Fabre to reimburse global development costs through BLA transfer; manufacturing transition planned at BLA transfer.
Atara plans to submit tab-cel BLA for PTLD to FDA in Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.